

# Serum Apelin and Obesity-Related Complications in Egyptian Children

Maged A. El Wakeel<sup>1\*</sup>, Ghada M. El-Kassas<sup>1</sup>, Alyaa H. Kamhawy<sup>1</sup>, Essam M. Galal<sup>1</sup>, Maysa S. Nassar<sup>1</sup>, Elsayed Mahmoud Hammad<sup>2</sup>, Salwa Refat El-Zayat<sup>3</sup>

<sup>1</sup>Child Health Department, Medical Division, National Research Centre, Cairo, Egypt; <sup>2</sup>Clinical Nutrition Department, National Nutrition Institute, Cairo Egypt; <sup>3</sup>Department of Medical Physiology, Medical Division, National Research Centre, Cairo, Egypt

## Abstract

**Citation:** El Wakeel MA, El-Kassas GM, Kamhawy AH, Galal EM, Nassar MS, Hammad EM, El-Zayat SR. Serum Apelin and Obesity-Related Complications in Egyptian Children. Open Access Maced J Med Sci. <https://doi.org/10.3889/oamjms.2018.312>

**Keywords:** Apelin; Obesity; Children; Metabolic syndrome

**\*Correspondence:** Maged A. El Wakeel. Child Health Department, Medical Division, National Research Centre, Cairo, Egypt. E-mail: [maged\\_elwakeel@yahoo.com](mailto:maged_elwakeel@yahoo.com)

**Received:** 27-May-2018; **Revised:** 23-Jul-2018; **Accepted:** 27-Jul-2018; **Online first:** 17-Aug-2018

**Copyright:** © 2018 Maged A. El Wakeel, Ghada M. El-Kassas, Alyaa H. Kamhawy, Essam M. Galal, Maysa S. Nassar, Elsayed Mahmoud Hammad, Salwa Refat El-Zayat. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0)

**Funding:** This research did not receive any financial support

**Competing Interests:** The authors have declared that no competing interests exist

**BACKGROUND:** The rapidly increasing prevalence of childhood obesity became a major burden on health worldwide, giving an alarm to clinicians and researchers. Adipocytes act as an active endocrine organ by releasing plenty of bioactive mediators (adipokines) that play a major role in regulating metabolic processes. Apelin is a recently identified adipokine that is expressed in adipocytes.

**AIM:** The current work aimed to uncover the relation between serum apelin and childhood obesity and its related complications as hypertension and hyperglycemia

**METHOD:** A group of 50 obese and 31 non-obese; sex- and age-matched children were enrolled in our study with a mean age of (9.5 ± 2.1) and (8.7 ± 1.3) respectively. Anthropometric measurements, blood pressure, were assessed in all studied participants, we also determined the lipid profile, serum insulin, fasting blood glucose (FBG) level, HOMA-IR and serum apelin.

**RESULTS:** Obese children had higher levels of HbA1c, FBG, serum insulin, HOMA-IR, total cholesterol, triglycerides, low-density lipoprotein (LDL) and diastolic blood pressure (DBP Z-score); compared to controls (all P < 0.05). Apelin was significantly higher in obese children versus controls and correlated positively with BMI Z-Score (P = 0.008), DBP Z-Score (P = 0.02), cholesterol, TG (both P = 0.02), serum insulin (P = 0.003), FBG and HOMA-IR (both P = 0.001). Linear regression analysis showed that FBG was the most effective factor in predicting the level of serum apelin (P = 0.04).

**CONCLUSION:** This work supports the hypothesis that apelin may have a crucial role in the pathogenesis of health hazards related to obesity in children including insulin resistance, hypertension and a higher risk of occurrence of metabolic syndrome.

## Introduction

Obesity in childhood is related to a large number of metabolic disorders,

including insulin resistance [1], dyslipidemia [2], hyperglycemia [3], type 2 diabetes mellitus [4], and the risk of cardiovascular complications [5].

Moreover, obese children tend to become obese adults [6]. However, studying childhood obesity is important to reduce its incidence and the possibility of developing obesity-related complications and other metabolic diseases.

Adipose tissue depots are the most important target to mediate significant immune cells infiltration contributing to systemic inflammation and insulin resistance in obese humans [7]. They represent powerful acting endocrine organs by releasing a huge amount of bioactive adipokines which play an effective role in regulating glucose homeostasis and inflammatory process [8]. This pattern of secretion reflects adipose tissue function and accounts essential for detecting the human susceptibility to develop cardiovascular and metabolic complications of obesity [9].

On initiating adipose tissue inflammation, adipokine release is markedly produced by a

diabetogenic, pro-inflammatory and atherogenic mode [10].

The recently known adipokine, Apelin which is a peptide of a 12-amino acid, encoded by the APLN gene and expressed in human adipocytes [11]. Apelin synthesis in adipocytes is stimulated by insulin, and its serum levels are found to be higher about diabetes mellitus, hyperinsulinemia and insulin resistance [12] [13].

Apelin expression helps in regulation of blood pressure [14], cardiac contractility [15], fluid balance [16] and activation of ACTH release by the pituitary [17]. Most of the previously mentioned studies demonstrate that contention presents around the levels and the associations of apelin in metabolic and cardiovascular disorders. Although relations have been reported between apelin and atopic dermatitis [18] and insulin resistance in adolescents with polycystic ovary syndrome [19].

Till now, there is no acceptance on if apelin levels have a direct relation with childhood obesity or not. So, this work aimed to study the relations between apelin levels and obesity in children and to find out the associations between those levels and obesity-related complications including hyperlipidemia, insulin resistance and hypertension.

## Patients and Methods

This case-control study included 81 children classified as 50 obese children compared to 31 healthy control who were recruited from child health Clinic in Medical and Scientific Centre of Excellence, National Research Center.

This includes full personal, history of systemic diseases, drug administration (as corticosteroids), and symptoms covering various systems, and family history of chronic non-communicable diseases (obesity, diabetes, cardiovascular diseases and hypertension).

All anthropometric measurements have been obtained using standardised equipment and following the recommendations of the International Biological program [20].

Assessment of body mass index (BMI) was done using categories reported by the World Health Organization (WHO) Child Growth Charts Standards for age and sex defined as the weight in kilograms divided by the square of the height ( $\text{kg}/\text{m}^2$ ) [21]. Weight for age, height for age and BMI Z-score were determined using the new WHO reference [22].

Waist Circumference was measured using inelastic insertion tape to the nearest 0.1 cm, with the subject in a standing position; the tape was applied

horizontally midway between the lowest rib margin and the iliac crest. Assessment of waist circumference was done using categories reported by Fernandez et al., 2004 [23]. Thorough medical general examination (head & neck, chest, heart, abdomen, upper & lower limbs) including measurement of systolic blood pressure (SBP) and diastolic blood pressure (DBP) then blood pressure Z-score was determined using the German references [24].

Blood samples were withdrawn from patients and controls after overnight fasting (> 12 hours). Fasting venous blood samples were collected in heparinised centrifuge tubes. Serum was separated by centrifugation (3000 rpm, 15 min). Separated serum aliquots were removed and stored frozen at  $-20^{\circ}\text{C}$  until further analyses were carried out, following tests were performed: Fasting serum glucose, fasting serum insulin, Cholesterol, Triglycerides (TG), high-density lipoprotein (HDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol were measured by calorimetric method. While serum apelin levels measured by quantitative commercial enzyme-linked immunosorbent assay ELISA kit supplied from Elabscience Biotechnology Co., Ltd, WuHan, China-Catalog No: E-EL-H0456 ([www.elabscience.com](http://www.elabscience.com)), detection range was between 62.5-400 pg/ml [25].

Insulin resistance was estimated by using the Homeostasis Model Assessment for insulin resistance (HOMA-IR), which was calculated according to the known formula, Insulin resistance being defined as a HOMA-IR index > 3.16). The greater the HOMA-IR value, the greater the level of insulin resistance [26].

Data management and analysis were performed using the Statistical Package for Social Sciences (SPSS) v. 21.

Numerical data were summarised using means  $\pm$  standard deviations. Comparisons between groups for normally distributed numeric variables were made using the Student's t-test while for non-normally distributed numeric variables were done by Mann-Whitney test. To measure the strength of association between numeric variables, Pearson's correlation coefficients were computed. All p-values are two-sided. Linear regression analysis was performed to predict risk factors significantly associated with an increased level of Apelin. P value was considered statistically significant when it was less than 0.05.

## Results

Fifty obese and thirty-one non-obese Egyptian children were included in this study; all were age- and sex-matched. Mean age was  $9.5 \pm 2.1$  and  $8.7 \pm 1.3$  years in obese children and control groups, respectively.

**Table 1: Anthropometric data of obese children versus controls**

| variable                    | Obese (n = 50)<br>Mean ± SD | Control (n = 31)<br>Mean ± SD | P-value |
|-----------------------------|-----------------------------|-------------------------------|---------|
| Age                         | 9.5 ± 2.1                   | 8.7 ± 1.3                     | 0.185   |
| Wt. z-score                 | 2.4 ± 1.1                   | 0.97 ± 0.42                   | 0.000*  |
| Ht. z-score                 | -0.7 ± 0.98                 | -0.9 ± 1.2                    | 0.456   |
| BMI z-score                 | 2.8 ± 0.7                   | 1.6 ± 0.6                     | 0.000*  |
| (DBP) Z-Score               | 0.7 ± 0.8                   | 0.2 ± 0.4                     | 0.013*  |
| (SBP) Z-score               | 0.4 ± 0.8                   | 0.1 ± 0.7                     | 0.178   |
| Waist circumference         | 99.4 ± 17.5                 | 64.7 ± 10.9                   | 0.000*  |
| Hip circumference           | 110.5 ± 16.8                | 86.7 ± 12.2                   | 0.000*  |
| Waist/hip ratio (WHR)       | 0.9 ± 0.2                   | 0.8 ± 0.3                     | 0.04*   |
| Mid arm circumference (MAC) | 32.1 ± 6.3                  | 17.3 ± 4.2                    | 0.000*  |

\* (P ≤ 0.05) is significant.

Table 1 shows that the obese group had significantly higher weight Z-score, BMI Z-score, DBP Z-score, waist circumference, hip circumference, WHR, MAC (all P < 0.05) than the control group.

**Table 2: Biochemical features of the studied groups**

| Variable                    | Obese (n = 50)<br>Mean ± SD | Control (n = 31)<br>Mean ± SD | P-value |
|-----------------------------|-----------------------------|-------------------------------|---------|
| Apelin                      | 2531 ± 547.8                | 1107.1 ± 436.7                | 0.000** |
| Cholesterol                 | 196.7 ± 41.9                | 94.5 ± 11.1                   | 0.000** |
| TG                          | 114.6 ± 34.4                | 83.7 ± 20.6                   | 0.000** |
| HDL                         | 45.3 ± 9.5                  | 53.3 ± 8.2                    | 0.000** |
| LDL                         | 121.4 ± 37.4                | 38.8 ± 8.4                    | 0.000** |
| Fasting blood Glucose (FBG) | 98.8 ± 16.4                 | 73.3 ± 12.9                   | 0.000** |
| Insulin                     | 15.1 ± 3.9                  | 9.4 ± 2.3                     | 0.038*  |
| HOMA-IR                     | 4.7 ± 1.3                   | 1.8 ± 0.9                     | 0.001*  |

\* Significant difference (P ≤ 0.05); \*\* Highly significant difference (P ≤ 0.01).

Obese children had significantly higher Cholesterol, TG, LDL, FBG, Insulin, HOMA-IR, and significantly low HDL compared to the control group. Also apelin levels were found to be higher in obesity group (Table 2).




Figure 1: Correlation between apelin level and diastolic blood pressure in obese cases

Correlation analysis of levels of serum apelin with anthropometric parameters and biochemical findings showed significant positive correlations between apelin and weight z score, BMI z score, waist, SBP, DBP z score (Figure 1), cholesterol, TG, Glucose, insulin and HOMA-IR (Figure 2) in the obese group.

No correlations were found between apelin levels and age, height, skinfold thickness, WHR, MAC, HDL, LDL.




Figure 2: Correlation between apelin level and HOMA-IR in obese cases

## Discussion

Obesity is considered a widely spread chronic illness and a major risk factor for the development of metabolic syndrome, type 2 diabetes mellitus and cardiovascular diseases [27]. Many studies have agreed that visceral obesity is strongly related to hypertension, dyslipidemia, hyperglycemia, and IR [28]. Severe adiposity may be the cause of some metabolic diseases such as type 2 diabetes (T2D), hypertension, insulin resistance, polycystic ovarian diseases and some types of cancer [29].

**Table 3: Predictive factors for an increased level of Apelin in obese children as estimated by linear regression**

| Variable    | Apelin |        |
|-------------|--------|--------|
|             | B      | Sig.   |
| BMI Z-score | 0.176  | 0.605  |
| SBP Z-score | 0.266  | 0.132  |
| DBP Z-Score | 0.037  | 0.842  |
| Cholesterol | 0.160  | 0.344  |
| TG          | 0.117  | 0.402  |
| FBG         | 0.455  | 0.038* |
| Insulin     | 0.488  | 0.371  |
| HOMA-IR     | -0.622 | 0.308  |

\*P < 0.05, the relationship is statistically significant; Factors entered: BMI, SBP Z-score, DBP Z-score, TG, Cholesterol, glucose, Insulin, HOMA-IR; Dependent variable: Apelin; Linear regression analysis showed that FBG was the main predictor serum apelin levels (P = 0.038).

Adipose tissue hormones called adipokines such as adiponectin, leptin, and apelin have a major role in obesity-related comorbidities and complications [12] [30]. High plasma levels of apelin have been detected by many authors in severe obesity and related to adiposity [31] [32].

The current work investigated the data of obese and non-obese groups of Egyptian children to find out correlations if present between apelin and obesity-related hazards, especially insulin resistance, hyperlipidemia, hypertension, and insulin sensitivity.

Serum insulin, TG, TC, LDL, and HOMA-IR were found to be significantly higher in all obese subjects when compared to controls in our study, these results were in agreement with Ba et al., 2014

[33], also we observed a significantly higher Apelin level in obese cases when compared to non-obese and this agreed with Boucher et al., 2005 [12] who found similar results and supposed that adipose tissue is a major source of apelin release, and that expression of apelin and apelin receptors (APJ) both increase in fat cells of obese subjects.

In the current study, we found that serum apelin levels were positively correlated with BMI. This came in agreement with a study done by Sheibani et al., 2012 supposing an important role of apelin in the pathogenesis of obesity and obesity-related complications [34]. Also, many studies revealed that apelin levels were higher in obese individuals in comparison to none-obese and correlated positively with BMI [31] [32]. In contrast, Reinehr et al., 2011 found that changes in apelin levels were not linked to weight reduction in obese children in a study assessed risk factors before and after one year of regular lifestyle modulations [35].

Moreover, in our study we found that there was a significantly positive correlation between Apelin and insulin, similar finding had been detected by other authors and explained by that the increased levels of both serum apelin and insulin could reflect impairment apelin homeostasis and also supposed that higher serum insulin concentrations could increase serum apelin levels [12].

In the current work, there was a significant increase in HOMA-IR in obese children in comparison to control group, also we found a significant positive correlation between Apelin and HOMA-IR and this in concordance with Li et al., 2006 who described a positive correlation with HOMA-IR in patients with type 2 diabetes and impaired glucose tolerance [36].

There is a potent correlation between obesity and parameters of insulin sensitivity caused by apelin released by adipose tissue [12]. It was mentioned that apelin suppresses the secretion of insulin plasma systems [37] [38]. Many authors also suggested that apelin may act as powerful insulin sensitising factor and could be a potent target for diabetes elimination and management due to its ability to increase insulin sensitivity [11].

In the present study, we observed a significant difference in diastolic blood pressure between obese and control groups, and there was a significant positive correlation between Apelin and SBP, DBP. These findings don't agree with Samir et al., 2015, who found a similar increase in serum apelin in obese hypertensive and nonhypertensive obese individuals but they found no correlation between systolic blood pressure, diastolic blood pressure, and serum apelin [38]. Also, Rittig et al., 2011, who evaluated the relation between apelin serum levels, body fat distribution and insulin sensitivity/resistance as dependent cardiovascular risk factors; blood pressure was reported to be unaffected by serum apelin levels [39].

In conclusion, apelin levels are significantly higher in obese children when compared to control group and correlate significantly with insulin, HOMA-IR, lipid profile and hypertension in these children suggesting that this adipokine may act as potential biomarkers for evaluation of metabolic risk factors in obesity.

Further studies with large sample size are in need to explain the role and mechanisms of action of apelin in association with obesity-related markers and metabolic diseases

## References

1. Caprio S. Insulin resistance in childhood obesity. *Journal of pediatric endocrinology & metabolism: JPEM*. 2002; 15:487-92. PMID:12017221
2. Kwiterovich PO, Jr. Recognition and management of dyslipidemia in children and adolescents. *Journal of Clinical Endocrinology and Metabolism*. 2008; 93:4200–4209. <https://doi.org/10.1210/jc.2008-1270> PMID:18697860
3. Weiss R, Kaufman FR. Metabolic complications of childhood obesity: identifying and mitigating the risk. *Diabetes Care*. 2008; 31(Suppl 2): 310–316. <https://doi.org/10.2337/dc08-s273> PMID:18227502
4. Arslanian S. Type 2 diabetes in children: clinical aspects and risk factors. *Hormone Research*. 2002; (Suppl 1):19–28. <https://doi.org/10.1159/000053308>
5. Mattsson N, Rönkä T, Juonala M, Viikari JS, Raitakari OT. Childhood predictors of the metabolic syndrome in adulthood. The Cardiovascular Risk in Young Finns Study. *Annals of Medicine*. 2008; 40(7):254–252. <https://doi.org/10.1080/07853890802307709> PMID:18728920
6. Pietrobelli A, Espinoza MC, De Cristofaro P. Childhood obesity: looking into the future. *Angiology*. 2008; (Suppl 2):30–33. <https://doi.org/10.1177/0003319708318788> PMID:18504263
7. Odegaard JI, Chawla A. Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. *Science*. 2013; 339:172-177. <https://doi.org/10.1126/science.1230721> PMID:23307735 PMID:PMC3725457
8. Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. *Mol Med*. 2008; 14:741-751. <https://doi.org/10.2119/2008-00058.Rabe> PMID:19009016 PMID:PMC2582855
9. Bays HE. "Sick fat," metabolic disease, and atherosclerosis. *Am J Med*. 2009; 122: S26-37. <https://doi.org/10.1016/j.amjmed.2008.10.015> PMID:19110085
10. Blüher M. Adipose tissue dysfunction in obesity. *Exp Clin Endocrinol Diabetes*. 2009; 117: 241-250. <https://doi.org/10.1055/s-0029-1192044> PMID:19358089
11. Castan-Laurell I, Dray C, Knauf C, Kunduzova O, Valet P. Apelin, a promising target for type 2 diabetes treatment? *Trends in Endocrinology and Metabolism*. 2012; 23:234–241. <https://doi.org/10.1016/j.tem.2012.02.005> PMID:22445464
12. Boucher J, Masri B, Daviaud D, Gesta S, Guigné C, et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. *Endocrinology*. 2005; 146:1764-1771. <https://doi.org/10.1210/en.2004-1427> PMID:15677759
13. Sabry RN, El Wakeel MA, El-Kassas GM, Amer AF, El Batal WH, El-Zayat SR. Serum Apelin: A New Marker of Early Atherosclerosis in Children with Type 1 Diabetes Mellitus. *Open Access Maced J Med Sci*. 2018; 6(4):613-617.

- <https://doi.org/10.3889/oamjms.2018.144> PMID:29731925  
PMCID:PMC5927488
14. Tatemoto K, Takayama K, Zou MX, Kumaki I, Zhang W, et al. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. *Regulatory Peptides*. 2001; 99:87–92. [https://doi.org/10.1016/S0167-0115\(01\)00236-1](https://doi.org/10.1016/S0167-0115(01)00236-1)
  15. Szokodi I, Tavi P, Foldes G, Voutilainen-Myllyla S, Iivonen M, et al. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. *Circulation Research*. 2002; 91:434–440. <https://doi.org/10.1161/01.RES.0000033522.37861.69> PMID:12215493
  16. Taheri S, Murphy K, Cohen M, Sujkovic E, Kennedy A, et al. The effects of centrally administered apelin-13 on food intake, water intake and pituitary hormone release in rats. *Biochemical and Biophysical Research Communications*. 2002; 291:1208–1212. <https://doi.org/10.1006/bbrc.2002.6575> PMID:11883945
  17. Reaux-Le Goazigo A, Alvear-Perez R, Zizzari P, Epelbaum J, BLuet-Pajot MT, et al. Cellular localization of apelin and its receptor in the anterior pituitary: evidence for a direct stimulatory action of apelin on ACTH release. *American Journal of Physiology, Endocrinology, and Metabolism*. 2007; 292:E7–15. <https://doi.org/10.1152/ajpendo.00521.2005> PMID:16896162
  18. Machura E, Szczepanska M, Ziora K, Ziora D, Swietochowska E, et al. Evaluation of adipokines: apelin, visfatin, and resistin in children with atopic dermatitis. *Mediators of Inflammation* 2013; 2013.
  19. Cekmez F, Cekmez Y, Pirgon O, Canpolat FE, Aydoniz S, et al. Evaluation of new adipocytokines and insulin resistance in adolescents with polycystic ovary syndrome. *European Cytokine Network*. 2011; 22:32–37. PMID:21411410
  20. Hiernaux J, Tanner JM. Growth and physical studies. In: *Human Biology: A guide to field methods*. Eds. Weiner JS, Lourie SA, IBP. London, Blackwell Scientific Publications. Oxford: U.K., 1969. PMID:5403554
  21. WHO. World Health Organization Anthroplus for personal computers. Software for assessing growth of the world's children and adolescents, 2007. <http://www.who.int/growthref/tools/en/>
  22. WMGRS. Members of the WHO Multicenter Growth Reference Study Group. WHO child growth standards: length/height-for age, weight-for-age, weight-for-length, weight-for-height and body mass index for age: methods and development. In: WHO Press, editors. *WHO Child Growth Standards*. Available in [http://www.who.int/childgrowth/standards/Technical\\_report.pdf](http://www.who.int/childgrowth/standards/Technical_report.pdf).
  23. Fernandez J, Redden D, Pietrobelli A, Allison D. Waist circumference percentiles in nationally representative samples of African-American, European-American, and Mexican-American children and adolescents. *Journal of Pediatrics*. 2004; 145(4):439–444. <https://doi.org/10.1016/j.jpeds.2004.06.044> PMID:15480363
  24. Wühl E, Witte K, Soergel M, Mehls O, Schaefer F; German Working Group on Pediatric Hypertension. Distribution of 24-h ambulatory blood pressure in children: Normalized reference values and role of body dimensions. *J Hypertens*. 2002; 20(10):1995–2007. <https://doi.org/10.1097/00004872-200210000-00019> PMID:12359978
  25. Principe A, Melgar-Lesmes P, Fernández-Varo G, del Arbol LR, Ros J, et al. The hepatic apelin system: a new therapeutic target for liver disease. *Hepatology*. 2008; 48:1193–1201. <https://doi.org/10.1002/hep.22467> PMID:18816630
  26. Keskin M, Kurtoglu S, Kendirci M, Atabek ME, Yazici C. Homeostasis Model Assessment Is More Reliable Than the Fasting Glucose/Insulin Ratio and Quantitative Insulin Sensitivity Check Index for Assessing Insulin Resistance Among Obese Children and Adolescents. *Pediatrics*. 2005; 115:e500. <https://doi.org/10.1542/peds.2004-1921> PMID:15741351
  27. Mirzaei K, Hossein-Nezhad A, Aslani S, Emamgholipour S, Karimi M, et al. Energy Expenditure Regulation Via Macrophage Migration Inhibitory Factor (MIF) in Obesity and In Vitro Anti-MIF Effect of *Alpinia Officinarum* Hance Extraction. *Endocr Pract*. 2011; 18:39–48. <https://doi.org/10.4158/EP11116.OR> PMID:21803717
  28. Van Pelt RE, Jankowski CM, Gozansky WS, Schwartz RS, Kohrt WM. Lower-body adiposity and metabolic protection in postmenopausal women. *J Clin Endocrinol Metab*. 2005; 90:4573–4578. <https://doi.org/10.1210/jc.2004-1764> PMID:15886255  
PMCID:PMC2819700
  29. Gómez-Ambrosi J, Salvador J, Silva C, Pastor C, Rotellar F, Gil MJ, Cienfuegos JA, Frühbeck G. Increased cardiovascular risk markers in obesity are associated with body adiposity: role of leptin. *Thromb Haemost*. 2006; 95(6):991–6. <https://doi.org/10.1160/TH06-02-0079> PMID:16732378
  30. Garcia-Diaz D, Campion J, Milagro F, et al. Adiposity dependent apelin gene expression: relationships with oxidative and inflammation markers. *Mol Cell Biochem*. 2007; 305:87–94. <https://doi.org/10.1007/s11010-007-9531-5> PMID:17594060
  31. Higuchi K, Masaki T, Gotoh K, Chiba S, Katsuragi I, Tanaka K, Kakuma T, Yoshimatsu H. Apelin, an APJ receptor ligand, regulates body adiposity and favors the messenger ribonucleic acid expression of uncoupling proteins in mice. *Endocrinology*. 2007; 148:2690–2697. <https://doi.org/10.1210/en.2006-1270> PMID:17347313
  32. Frier BC, Williams DB, Wright DC. Mitochondrial content the effects of apelin treatment on skeletal muscle. *Am J Physiol Regul Integr Comp Physiol*. 2009; 297:R1761–R1768. <https://doi.org/10.1152/ajpregu.00422.2009> PMID:19793954
  33. Ba HJ, Chen HS, Su Z, Du ML, Chen QL, Li YH, Ma HM. Associations between serum apelin-12 levels and obesity-related markers in Chinese children. *PLoS One*. 2014; 9(1):e86577. <https://doi.org/10.1371/journal.pone.0086577> PMID:24475149  
PMCID:PMC3903556
  34. Sheibani S, Hanachi P, Refahiat MA. Effect of aerobic exercise on serum concentration of apelin, TNF $\alpha$  and insulin in obese women. *Iran J Basic Med Sci*. 2012; 15(6):1196–1201. PMID:23653851  
PMCID:PMC3646232
  35. Reinehr T, Woelfle J, Roth CL. Lack of association between apelin, insulin resistance, cardiovascular risk factors, and obesity in children: a longitudinal analysis. *Metabolism Clinical and Experimental*. 2011; 60:1349–1354. <https://doi.org/10.1016/j.metabol.2011.02.005> PMID:21489579
  36. Li L, Yang G, Li Q, Tang Y, Yang M, et al. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. *Experimental and Clinical Endocrinology & Diabetes*. 2006; 114:544–548. <https://doi.org/10.1055/s-2006-948309> PMID:17177135
  37. Sorhede WM, Magnusson C, Ahren B. The apj receptor is expressed in pancreatic islets and its ligand, apelin, inhibits insulin secretion in mice. *Regul Pept*. 2005; 131:12–17. <https://doi.org/10.1016/j.regpep.2005.05.004> PMID:15970338
  38. Assaad SN, El-Aghoury AA, El-Sharkawy EM, Azzam EZ, Salah MA. Study of serum apelin and its relation to obesity-associated hypertension. *Egyptian Journal of Obesity, Diabetes and Endocrinology*. 2015; 1(1):28. <https://doi.org/10.4103/2356-8062.159990>
  39. Rittig K, Hildebrandt U, Thamer C, Staiger H, Peter A, Stefan N, et al. Apelin serum levels are not associated with early atherosclerosis or fat distribution in young subjects with increased risk for type 2 diabetes. *Exp Clin Endocrinol Diabetes*. 2011; 119:358–361. <https://doi.org/10.1055/s-0030-1268466> PMID:21264801